Cybersecurity for pacemakers, ICDs, CIEDs, and cardiac monitoring.
Cardiac implantable electronic devices (CIEDs) and remote monitoring platforms have a long history of high-profile cybersecurity recalls. We help cardiovascular manufacturers harden device-to-programmer, device-to-home-monitor, and home-monitor-to-cloud paths against the threats FDA reviewers now expect to see modeled.
Cardiac implantable electronic devices (CIEDs) carry the longest documented history of FDA cybersecurity advisories, 522 orders, and recalls. Reviewers, hospital procurement, and class-action attorneys all expect detailed, traceable evidence that lessons from past recalls are designed in.
A typical CIED ecosystem spans the implant, an in-clinic programmer, a home-monitor transmitter, a cellular or Wi-Fi backhaul, and a cloud follow-up portal feeding the EHR. Each link has been the entry point for at least one publicized vulnerability.
Typical clinical uses
Key data flows & integrations
Inductive and RF interfaces to in-clinic programmers must enforce mutual authentication, session keys, and anti-replay.
Cellular and Wi-Fi backhaul from home monitors needs certificate pinning, secure boot, and tamper-evident telemetry.
10+ year device lifetimes demand a postmarket vulnerability management plan and SBOM monitoring.
Cardiac implantable electronic devices (CIEDs) carry the longest documented history of FDA cybersecurity recalls and 522 orders - reviewers expect detailed evidence of the lessons learned.
Active fleets span multiple firmware generations and pairings; postmarket plans must address all simultaneously without breaking patient care.
Adding remote monitoring or changing crypto often requires a PMA Supplement - we structure delta documentation reviewers can approve quickly.
Health systems demand MDS2, SBOM, and pen test summaries up front - inconsistencies between these and the FDA submission stall sales.
Cyber findings sometimes drive 522/recall decisions. Premarket-time documentation of secure update mechanisms reduces that downstream burden.
What FDA scrutinizes
Cyber-only changes (remote monitoring add, crypto refresh) often require a Supplement; documentation must trace deltas back to the original PMA risk file.
Hospital procurement compares MDS2, SBOM, pen test summary, and IFU. Inconsistencies stall both clearance and sales.
A documented secure-update mechanism is the difference between a software patch and a 522 order.
We pair premarket work with a postmarket vulnerability management plan, SBOM monitoring, and a coordinated vulnerability disclosure (CVD) program - all required by FDA.
Yes - programmers are scoped as a connected system component. We test their OS hardening, software supply chain, and the inductive/RF link to the implant with mutual authentication and replay protections in scope.
Home transmitters are tested for cellular/Wi-Fi configuration, certificate validation and pinning, secure boot, and tamper-evident telemetry - plus the cloud APIs they call.
Yes - we deliver a delta threat model, updated SBOM, and incremental test report focused on the new remote-monitoring path so reviewers can see the change clearly.
We help you produce an MDS2 that's consistent with your SPDF and labeling so hospital security reviews don't contradict your FDA submission.
We document the secure-update mechanism (signed payloads, rollback protection, staged rollout) and the CVD process that triggers field updates - both expected by FDA reviewers.
Threat models, SBOMs, and pen testing tuned to BLE/proprietary RF and clinician programmers - built for 510(k) and PMA.
"Blue Goat Cyber's depth of expertise was impressive. We had no in-house cybersecurity experience, and their team guided us through every step of the FDA process. The penetration testing and SBOM testing were thorough and gave us complete confidence."
Cybersecurity for pacemakers, ICDs, CIEDs, and cardiac monitoring.
